Evidence map›Paper›PMID 37500754›Full record

ArticleCommunications biology2023

Nonclassical mechanisms to irreversibly suppress β-hematin crystal growth.

Wenchuan Ma, Victoria A Balta, Weichun Pan, Jeffrey D Rimer, David J Sullivan, Peter G Vekilov

Open access · goldAbstract read
In one paragraph

Article in Communications biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Genes and crystals are not so separate.Nature chemical biology · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Tartronic Acid as a Potential Inhibitor of Pathological Calcium Oxalate Crystallization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Wenchuan Ma *William A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, 77204, USA.
Victoria A Balta *W. Harry Feinstone Department of Molecular Microbiology and Immunology, Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA.ORCID 0000-0003-0685-6697
Weichun PanWilliam A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, 77204, USA.ORCID 0000-0002-4030-8363
Jeffrey D RimerWilliam A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, 77204, USA. jrimer@central.uh.edu.ORCID 0000-0002-2296-3428
David J SullivanW. Harry Feinstone Department of Molecular Microbiology and Immunology, Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA. dsulliv7@jhmi.edu.ORCID 0000-0003-0319-0578
Peter G VekilovWilliam A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, 77204, USA. vekilov@uh.edu.ORCID 0000-0002-3424-8720
University of Houston · USJohns Hopkins University · US

Funding

Dual artemisinin action combats resistanceR01AI150763 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SULLIVAN, DAVID JOSEPH, VEKILOV, PETER G · 2021 to 2025
$2.9M
Malaria and Mosquito/Tick-borne DiseasesT32AI138953 · NIAID · JOHNS HOPKINS UNIVERSITY · PI DAVID Joseph SULLIVAN · 2019 to 2026
$2.0M
NIAID NIH HHS R01 AI150763NIAID NIH HHS T32 AI138953
6 · The paper itself

Abstract

Hematin crystallization is an essential element of heme detoxification of malaria parasites and its inhibition by antimalarial drugs is a common treatment avenue. We demonstrate at biomimetic conditions in vitro irreversible inhibition of hematin crystal growth due to distinct cooperative mechanisms that activate at high crystallization driving forces. The evolution of crystal shape after limited-time exposure to both artemisinin metabolites and quinoline-class antimalarials indicates that crystal growth remains suppressed after the artemisinin metabolites and the drugs are purged from the solution. Treating malaria parasites with the same agents reveals that three- and six-hour inhibitor pulses inhibit parasite growth with efficacy comparable to that of inhibitor exposure during the entire parasite lifetime. Time-resolved in situ atomic force microscopy (AFM), complemented by light scattering, reveals two molecular-level mechanisms of inhibitor action that prevent β-hematin growth recovery. Hematin adducts of artemisinins incite copious nucleation of nonextendable nanocrystals, which incorporate into larger growing crystals, whereas pyronaridine, a quinoline-class drug, promotes step bunches, which evolve to engender abundant dislocations. Both incorporated crystals and dislocations are known to induce lattice strain, which persists and permanently impedes crystal growth. Nucleation, step bunching, and other cooperative behaviors can be amplified or curtailed as means to control crystal sizes, size distributions, aspect ratios, and other properties essential for numerous fields that rely on crystalline materials.

Indexed as

AntimalarialsMalariaQuinolinesArtemisininsCrystallizationHemeproteinsHeminHumansAntimalarialsartemisininArtemisininsHemeproteinsHeminhemozoinQuinolines

Identifiers

PMID37500754
PMCPMC10374632
OpenAlexW4385331182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.